..............page:123-124
..............page:125-126
..............page:127-129+133
..............page:130-133
..............page:134-136+153
..............page:137-143
..............page:144-146
..............page:147-148+160
..............page:149-153
..............page:154-160
Research progress of the novel adjuvant CpG ODN
LIU Li;WANG Ju-feng;LI Bo;National Center for Safety Evaluation of Drugs;National Institute for Food and Drug Control;Key Laboratory of Beijing for Nonclinical Safety Evaluation Research of Drugs;National Institute for Food and Drug Control;
..............page:161-170
FDA’s expedite development program for the therapies for serious conditions
DONG Jiang-ping;LI Mao-zhong;YAO Li-xin;SHAO Ying;ZHENG Qiang;Drug Registration Department;China Food and Drug Administration;Center for Pharmaceutical Information and Engineering Research;Peking University;Department of Industrial Engineering and Management;College of Engineering;Peking University;
..............page:171-182+202+183
..............page:184-188+209
..............page:189-195
..............page:196-202
..............page:203-209
..............page:210-214
..............page:215-218+240
..............page:219-225
..............page:226-231
Improved synthesis of retigabine
WANG Wei;YANG Jin-lu;ZHANG Yong;College of Chemical and Pharmaceutical Engineering;Hebei University of Science and Technology;State Key Laboratory Breeding Base-Key Laboratory of Molecular Chemistry for Drug of Hebei Province;
..............page:232-234
..............page:235-240
..............page:241-243+246
..............page:244-246